Effects of experimental hypothyroidism on the development of the hypothalamo-pituitary-adrenal axis in the rat.
Hypothyroid pups were obtained by adding methimazole in the mother's drinking water from day 15 of gestation and sacrificed at 4, 8 or 15 days. Circulating corticosterone decreased at all ages, while CBG concentrations diminished at day 4, increased at day 8 and did not change at day 15 in hypothyroid rats. As opposed to controls, plasma ACTH concentrations decreased steadily with age while there was an accumulation of ACTH in the anterior pituitary of hypothyroid 15-day-old rats. Anterior pituitary POMC contents were unaffected by the treatment. In the hypothalamic PVN, CRF mRNA levels in the total population of CRF-synthesizing cells and in the CRF+/AVP+ subpopulation were below those of controls whatever the age considered while AVP mRNA in the CRF+/AVP+ subpopulation did not change at day 4 and decreased at day 8 and 15 in hypothyroid animals. Both the number of cell bodies expressing detectable levels of CRF mRNA and the percentage of CRF and AVP colocalization decreased at day 4 and were unchanged thereafter. CRF and AVP immunoreactivity in the zona externa of the median eminence increased with age but was not affected by methimazole treatment. The concentration of AVP mRNA in the magnocellular cell bodies of the PVN and the SON as well as AVP immunoreactivity in the zona interna of the median eminence were not changed by the treatment at days 4 and 8. In hypothyroid 15-day-old rats, SON AVP mRNA increased, AVP immunoreactivity decreased while plasma osmolality was enhanced. In conclusion, our data demonstrate that experimental hypothyroidism impairs specifically the maturation of hypothalamic parvocellular CRF and AVP gene expression during the stress hyporesponsive period. These observations suggest that the physiological peak in plasma thyroxine concentrations that occur between day 8-12 may participate in the maturation of hypothalamic CRF- and AVP-synthesizing cells.
Dakine
N
N
Laboratoire des Interactions Fonctionnelles en Neuroendocrinologie, INSERM U 501, Université de la Méditerranée, UER de Médecine secteur Nord, Marseille, France.
Oliver
C
C
Grino
M
M
D000284:Administration, Oral; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000375:Aging; D000818:Animals; D001127:Arginine Vasopressin / Q000032:analysis / Q000235:genetics; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000032:analysis / Q000235:genetics; D004195:Disease Models, Animal; D005260:Female; D018507:Gene Expression Regulation, Developmental; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology / Q000503:physiopathology*; D007037:Hypothyroidism / Q000503:physiopathology*; D008713:Methimazole / Q000008:administration & dosage / Q000494:pharmacology; D010286:Paraventricular Hypothalamic Nucleus / Q000254:growth & development / Q000378:metabolism; D010903:Pituitary Gland, Anterior / Q000254:growth & development / Q000378:metabolism; D010913:Pituitary-Adrenal System / Q000502:physiology / Q000503:physiopathology*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011333:Pro-Opiomelanocortin / Q000032:analysis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D013495:Supraoptic Nucleus / Q000254:growth & development / Q000378:metabolism; D013972:Thyrotropin / Q000097:blood; D014156:Transcortin / Q000032:analysis
D001127:Arginine Vasopressin; D008713:Methimazole; D011333:Pro-Opiomelanocortin; D000324:Adrenocorticotropic Hormone; D013972:Thyrotropin; D014156:Transcortin; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone